Fangzhou Inc (6086) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Fangzhou Inc HK$0.28, price HK$0.85, upside -67.0%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Fangzhou Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
27‑month range HK$0.6500 – HK$7.96 · fair‑value band HK$0.2720 – HK$0.2805 · the HK$0.8500 price screens above the HK$0.2805 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Fangzhou in your weekly email
Every Wednesday you see whether Fangzhou is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Fangzhou Inc. provides online chronic disease management services in China. It operates through four segments: Online Retail Pharmacy Services; Comprehensive Medical Services; Wholesale; and Customized Content and Marketing Solutions.
Show more
Fangzhou Inc. provides online chronic disease management services in China. It operates through four segments: Online Retail Pharmacy Services; Comprehensive Medical Services; Wholesale; and Customized Content and Marketing Solutions. The company offers services through online chronic disease management platform to address the needs of patients with chronic disease, such as hypertension, cardiovascular and respiratory diseases. It also engages in the sales of pharmaceutical and healthcare products through online retail pharmacy service platform, third-party platforms, and offline retail pharmacies; and online consultation, e-prescription, physician consultation, physical examination, and surgery service, as well as wholesale of pharmaceutical products. Fangzhou Inc. was founded in 2015 and is based in Guangzhou, China.
Stock analysis
Fangzhou Inc (6086) currently trades at HK$0.8500, while our model-based Fair Value estimate is HK$0.2805, 67.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$0.8200 per share, and 5 of the 24 models we run sit above the HK$0.8500 price.
Bear case: the Asset-Based group reads lowest at HK$0.0900, and 19 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$0.2720 (bear) to HK$0.2805 (bull), the price of HK$0.8500 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Fangzhou Inc reported revenue of 3.5B CNY in FY2025 versus 1.8B CNY in FY2021, a compound +19.0%/yr. Reported net income was 11.8M CNY in FY2025.
Key figures
Market cap HK$1.1B (≈ $146M) · P/E ratio 83.5 · P/S ratio 0.28 · EPS (TTM) HK$0.0102 · Net margin 0.3% · Return on equity 8.3% · Return on assets (EBIT) −43.2% · Operating margin 0.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 80% below its 52-week high and 31% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −67%, 6086 screens richer than that median.
Fair Value models
Bear HK$0.2720Fair Value HK$0.2805Bull HK$0.2805
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0075 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+30.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−11.1% (2021) → 0.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +0.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 59 stocks
Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score53 · Above median
Fair Value upside−67.0% · Bottom 25%
Profitability
Return on equity (TTM)8.3% · Above median
Return on assets1.1% · Below median
Net margin (TTM)0.3% · Below median
Operating margin (TTM)0.0% · Below median
Growth and dividend
Revenue growth46.8% · Top 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/E (TTM)83.5× · Priciest 25%
P/B6.35× · Priciest 25%
P/S (TTM)0.28× · Cheaper than median
P/FCF14.9× · Priciest 25%
EV/EBITDA42.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 46
FUTURE (revenue growth)100· sector 26
PAST (return on equity)33· sector 22
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 65
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Fangzhou Inc Fair Value". https://www.fairvalue-calculator.com/stock/6086
Frequently asked questions
Is Fangzhou Inc (6086) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$0.2805 versus a price of HK$0.8500, about −67% upside (overvalued).
What is the fair value of 6086?
Our model-based fair value for Fangzhou Inc is HK$0.2805 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.8500.
What is the quality score of 6086?
Fangzhou Inc has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fangzhou Inc (6086)?
Our model-based price target is the fair value of HK$0.2805 (as of Sep 27, 2026) from 24 valuation models. Cautious scenario HK$0.2720, optimistic scenario HK$0.2805. It is a calculation from audited fundamentals, not an analyst target.
What is the Fangzhou Inc stock forecast for 2026?
Our models put fair value at HK$0.2805, about −67% upside versus a price of HK$0.8500 (overvalued). Cautious scenario HK$0.2720, optimistic scenario HK$0.2805. The calculation is refreshed regularly with new filings.
What is the revenue of Fangzhou Inc (6086)?
Fangzhou Inc reported trailing-twelve-month revenue of about 3.5B CNY (latest available figure, as of Sep 27, 2026).
What growth is priced into Fangzhou Inc (6086)?
For today's price to be fair in a discounted-cash-flow model, Fangzhou Inc would have to grow free cash flow by +2.4 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +19.0 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 6086 use?
Our models discount Fangzhou Inc at 13.3 %: a base by market capitalisation (micro), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Fangzhou Inc that is +2.4 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Fangzhou Inc (6086) delivered so far?
Over the past 4 years revenue at Fangzhou Inc grew +19.0 % a year. The price currently implies +2.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Fangzhou Inc (6086) growing?
The median revenue growth in the sector is +5.7 % a year. That is the yardstick for the growth priced into Fangzhou Inc (+2.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Fangzhou Inc (6086)?
The free-cash-flow yield on the price is 6.69 %: that much free cash flow Fangzhou Inc produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Fangzhou Inc (6086)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fangzhou Inc it is HK$0.2805 per share (as of Sep 27, 2026), against a price of HK$0.8500. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Fangzhou Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 6086 trades above its calculated fair value: price HK$0.8500, fair value HK$0.2805, a gap of about −67% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6086?
No. The price is what the market pays today (HK$0.8500); the fair value is what the company's own numbers justify (HK$0.2805). For Fangzhou Inc the two are HK$0.5695 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fangzhou Inc worth?
The market values Fangzhou Inc at about HK$1.1B (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.8500; our models calculate a fair value of HK$0.2805 per share.
What do the bullish and bearish scenarios say about 6086?
Our models span a range for Fangzhou Inc: cautious scenario HK$0.2720, base HK$0.2805, optimistic HK$0.2805 per share (as of Sep 27, 2026, price HK$0.8500). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6086?
Fangzhou Inc trades at a price-to-earnings ratio of 83.5 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.2805 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 47.8 (reported 83.5). Other multiples: P/B 6.4, P/S 0.3, EV/EBITDA 42.4.
How solid is the balance sheet of Fangzhou Inc (6086)?
Balance-sheet figures for Fangzhou Inc (as of Sep 27, 2026): return on equity 8.3%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 6086 from its 52-week high?
Fangzhou Inc trades at HK$0.8500, about 80% below its 52-week high of HK$4.24 and 31% above the low of HK$0.6500 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.2805 is for.
Which stocks are comparable to Fangzhou Inc?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fangzhou Inc stock attractive at the current price?
The data as of Sep 27, 2026: price HK$0.8500, calculated fair value HK$0.2805 (−67%), Quality Score 53/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6086 calculated?
We run Fangzhou Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.2805, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Fangzhou Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fangzhou Inc (6086)?
The closing price on Sep 30, 2026 was HK$0.8500. Our model-based fair value is HK$0.2805, about −67% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fangzhou Inc right now?
The price sits above even our optimistic bull case (HK$0.2805). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (HK$0.2720 to HK$0.2805), unusually little disagreement for a valuation.
Key figures of Fangzhou Inc
How large is the market capitalisation of Fangzhou Inc (6086)?
The market capitalisation of Fangzhou Inc is HK$1.1B (≈ $146M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fangzhou Inc (6086)?
The price-to-sales ratio of Fangzhou Inc is 0.28 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fangzhou Inc (6086)?
Earnings per share at Fangzhou Inc are HK$0.0102 (price ÷ EPS = P/E 83.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Fangzhou Inc (6086)?
The net margin of Fangzhou Inc is 0.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fangzhou Inc (6086)?
The return on equity (ROE) of Fangzhou Inc is 8.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fangzhou Inc (6086)?
On an EBIT basis the return on assets of Fangzhou Inc is −43.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fangzhou Inc (6086)?
The operating margin of Fangzhou Inc is 0.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fangzhou Inc (6086)?
Revenue at Fangzhou Inc is growing +46.8% versus a year earlier (3y avg +17.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Fangzhou Inc (6086) hold?
Fangzhou Inc holds more cash than debt, 261M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Fangzhou Inc in the live analysis
One click puts Fangzhou Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
